PCA
RARE icon

Pallas Capital Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Pallas Capital Advisors’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,904
Closed -$598K – 624
2024
Q3 		$598K Buy
+10,904
New +$555K 0.03% 318

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Pallas Capital Advisors's RARE Position: Q4 2024 in Review

Pallas Capital Advisors sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2024, closing a stake of 10,904 shares — an estimated $598K sold.

Pallas Capital Advisors first reported a position in RARE in Q3 2024 and held it in 1 quarter. The position peaked at $598K in Q3 2024. 312 funds tracked by Wall St. Rank hold RARE as of Q4 2024.

  • Pallas Capital Advisors reported no remaining Ultragenyx Pharmaceutical position as of Q4 2024 after selling out during the quarter.
  • Pallas Capital Advisors sold 10,904 Ultragenyx Pharmaceutical shares in Q4 2024, an estimated $598K.
  • Pallas Capital Advisors first reported a position in Ultragenyx Pharmaceutical in Q3 2024 and held it in 1 quarter.
  • Pallas Capital Advisors's Ultragenyx Pharmaceutical position peaked at $598K in Q3 2024.
  • 312 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2024.

Based on Pallas Capital Advisors's 13F filing for Q4 2024, filed 13 Jan 2025.